Pulse Therapeutics is nearing its $1.5 million goal in an active fundraising effort that has so far brought in just over $1 million, according to a SEC filing.
St. Louis-based Pulse Therapeutics is developing stroke treatment technologies based on tiny, biologically safe iron particles that could deliver drug therapy.
Pulse attracted 3 unnamed investors, who purchased equity at a minimum investment of $25,000 apiece. Pulse is still seeking another $475,000 to close the round, according to a regulatory filing.
